236 related articles for article (PubMed ID: 18082568)
1. Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome.
Murdaca G; Contini P; Setti M; Cagnati P; Villa R; Lantieri F; Indiveri F; Puppo F
Hum Immunol; 2007 Nov; 68(11):894-900. PubMed ID: 18082568
[TBL] [Abstract][Full Text] [Related]
2. Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution.
Murdaca G; Contini P; Setti M; Cagnati P; Lantieri F; Indiveri F; Puppo F
Clin Immunol; 2009 Nov; 133(2):238-44. PubMed ID: 19762282
[TBL] [Abstract][Full Text] [Related]
3. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
4. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
Brumme ZL; Brumme CJ; Chui C; Mo T; Wynhoven B; Woods CK; Henrick BM; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2007 Jun; 195(11):1694-704. PubMed ID: 17471440
[TBL] [Abstract][Full Text] [Related]
5. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
6. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
7. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy.
Chitra P; Bakthavatsalam B; Palvannan T
Clin Chim Acta; 2011 May; 412(11-12):1151-4. PubMed ID: 21300045
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of anti-R7V antibodies in HIV-infected patients under highly active antiretroviral therapy].
Ergünay K; Altinbaş A; Calik Başaran N; Unal S; Us D; Karabulut E; Ustaçelebi S
Mikrobiyol Bul; 2008 Jul; 42(3):413-9. PubMed ID: 18822884
[TBL] [Abstract][Full Text] [Related]
9. Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome.
Kitchen CM; Kitchen SG; Dubin JA; Gottlieb MS
Clin Infect Dis; 2001 Aug; 33(4):466-72. PubMed ID: 11462181
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy.
Gaardbo JC; Nielsen SD; Vedel SJ; Ersbøll AK; Harritshøj L; Ryder LP; Nielsen JO; Kolte L
Clin Exp Immunol; 2008 Oct; 154(1):80-6. PubMed ID: 18821942
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
12. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
Simonelli C; Tedeschi R; Gloghini A; Bortolin MT; Spina M; Bidoli E; Cinelli R; De Paoli P; Carbone A; Tirelli U
Clin Infect Dis; 2005 Apr; 40(7):1022-7. PubMed ID: 15824995
[TBL] [Abstract][Full Text] [Related]
13. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
[TBL] [Abstract][Full Text] [Related]
14. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients.
Rodriguez B; Woolley I; Lederman MM; Zdunek D; Hess G; Valdez H
J Infect Dis; 2003 Feb; 187(3):504-7. PubMed ID: 12552436
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
16. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
[TBL] [Abstract][Full Text] [Related]
18. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy.
Orsilles MA; Pieri E; Cooke P; Caula C
APMIS; 2006 Jan; 114(1):55-60. PubMed ID: 16499662
[TBL] [Abstract][Full Text] [Related]
19. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
[TBL] [Abstract][Full Text] [Related]
20. Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1.
Knapp DJ; Brumme ZL; Huang SY; Wynhoven B; Dong WW; Mo T; Harrigan PR; Brumme CJ
Clin Infect Dis; 2012 Jun; 54(11):1652-9. PubMed ID: 22460975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
